Sponsor study identifier
interventional
30
0 countries
N/A
Study Start
January 2013
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2014
Actual (reported)Study Completion
August 2014
Actual (reported)combining the non-surgical therapy with a well-tolerated substance that can stimulate protective immune responses like B-glucan, might effectively mount resolution pathways contributing to resolving of the chronic lesion observed in aggressive forms of periodontal disease.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2014
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2013
Date type not reportedThis date has not been verified as actual or estimated.
June 2014
Actual (reported)August 2014
Actual (reported)March 6, 2015
Actual (reported)March 30, 2015
Actual (reported)June 9, 2015
Actual (reported)Assessment of Change in Clinical Attachment Level (CAL)
It is the distance from the base of the pocket till the cemento-enamel junction using Williams graduated probe
Day 0 and day 91 post therapy
Pocket Depth (PD)
Day 0 and day 91 post therapy
Gingival Index (GI)
Day 0 and day 91 post therapy
Matrix Metallo-proteinase (MMP-1&9)
Day 0 and day 91 post therapy
Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
• Prakasam A; Elavarasu SS; Natarajan RK. Antibiotics in the management of aggressive periodontitis. J Pharm Bioallied Sci. 2012; 4 (Suppl 2): S252-5. • Aurer A; Recent Advances in periodontology. Med Sci 2012; 38: 49-59. • Acar NN; Noyan Ü; Kuru L;Kadir T; Kuru B. Adjunctive systemic use of beta-glucan in the nonsurgical treatment of chronic periodontitis. Pathogenesis and treatment of periodontitis 2012; 11: 167-82. • Stashenko P; Wang CY; Riley E; Wu Y; Ostroff G; Niederman R. Reduction of infection-stimulated periapical bone resorption by the biological response modifier PGG Glucan. J Dent Res 1995; 74 (1):323-30. • Chaple CC; Srivastrava M; Hunter N; Failure of macrophage activation in destructive periodontal disease. J Pathol 1988; 186: pp.281-286.
No limitations or caveats were reported throughout the study period.
Hala H. Hazzaa, Professor
Al-Azhar University, Faculty of Dental and Oral Medicine (Girls Branch)
30 participants (actual enrollment reported by the registry).
First Submitted
March 6, 2015
First Posted
March 30, 2015
Study Start
January 2013
Date type not reportedRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Primary Completion
June 2014
Actual (reported)Study Completion
August 2014
Actual (reported)Last Updated
June 9, 2015
Results First Posted
June 9, 2015
Record last verified: 2015-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: